Glyburide and glimepiride pharmacokinetics in subjects with different CΥP2C9 genotypes

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 3, 2002, Pages 326-332

  Niemi, Mikko ^a,b   Cascorbi, Ingolf ^a,b   Timm, Ramona ^a,b   Kroemer, Heyo K ^a,b   Neuvonen, Pertti J ^a,b   Kivistö, Kari T ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; SULFONYLUREA DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; WILD TYPE;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOOD GLUCOSE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; POLYMORPHISM, GENETIC; STATISTICS, NONPARAMETRIC; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFONYLUREA COMPOUNDS;

EID: 0036736497     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.127495     Document Type: Article

References (27)

1. Pharmacokinetics of glyburide
2. Glimepiride. A review of its use in the management of type 2 diabetes mellitus
3. Hypoglycemic agents
4. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
5. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
6. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
7. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
8. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
9. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
10. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates
11. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
12. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
13. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
14. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
15. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3
16. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype
17. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
18. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans
19. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
20. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
21. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride
22. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride
23. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
24. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
25. How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport
26. In-vitro metabolism of celecoxib, a cyclo-oxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmacokinetics